Attendees: Dr. Tutag Lehr, Andrew Mac, James Miller, Brian Peltz, Dr. Anthony Ognjan, Dr. Steve Hadesman, Dr. Jayne Courts, Dr. Venkat Rao, Dr. James Matthews, Dr. Neff. A quorum was met.

Absent: Dr. Brad Uren

The MDHHS P & T committee was called to order at 6:05 pm by the chair, Dr. Vicki Tutag Lehr. The agenda was reviewed and accepted. Introductions were made and quorum established.

Conflict of interest statement was reviewed. Annual attestations were signed. None of the members had COI to report.

Review of the December meeting minutes were reviewed and accepted.

**MDHHS Updates:**

The Committee was provided Policy Updates regarding MTM Services, Legislative Updates, Pipeline Drugs and New Indications, a Hepatitis C Update and general clinical updates.

**Old Business:**

The committee reviewed topical NSAID’s and voted to put VOPAC on non-preferred status. Jardiance cardiovascular outcomes were reviewed.
New Drug Review:

The committee reviewed the following new drugs and approved that the following new agents reviewed be added to the formulary as non-preferred as follows:

1. Bromsite (bromfenac) ophthalmic drops - [PDL class: Ophthalmics: NSAIDS; non-preferred]
2. Byvalson (nebivolol/valsartan)- [PDL class: Antihypertensive Combinations: ARBs; non-preferred]
3. DermacinRx Therazole Pak (clotrimazole/betamethasone/zinc) - [PDL class: Antifungals: Topical; non-preferred]
4. Gonitro (nitroglycerin) sublingual powder - [Not a PDL Class; Add to MPPL with PA]
5. Invokamet XR (canagliflozin/metformin) tablets - [PDL class: Oral hypoglycemics: Combinations; non-preferred]
6. Micort-HC (hydrocortisone) cream – [PDL class: Topical Steroids: Low Potency; non-preferred]
7. Otovel (ciprofloxacin/fluocinolone) otic drops – [PDL class: Otic Quinolones; non-preferred]
8. Qbrelis (lisinopril) oral solutions – [PDL class: ACE Inhibitors; non-preferred]
9. Yosprala DR (aspirin/omeprazole) tablets – [PDL class: Platelet Aggregation Inhibitors; non-preferred]
10. Zurampic (lesinurad) tablets - [Not a PDL Class; Add to MPPL with PA]

Preferred Drug List Classes:

A Review of the following Preferred Drug Classes was performed and the following actions were taken.

A. Ophthalmics:
1. Glaucoma: Alpha-2 Adrenergics
   a. No change to the current classification of drug products – Approved as proposed

A. Ophthalmics:
1. Glaucoma: Alpha-2 Adrenergics
   a. No change to the current classification of drug products – Approved as proposed

2. Glaucoma: Beta Blockers
   a. Move betaxolol (generic for Betoptic) to non-preferred – Approved as proposed
3. **Glaucoma: Prostaglandin Inhibitors**  
a. No change to the current classification of drug products – Approved as proposed

4. **Glaucoma: Carbonic Anhydrase Inhibitors**  
a. No change to the current classification of drug products – Approved as proposed

5. **Glaucoma: Combination Alpha-2 Adrenergic/Beta Blocker**  
a. No change to the current classification of drug products – Approved as proposed

6. **Ophthalmic Antihistamines**  
a. **Move Patanol (olapatadine) to non-preferred** – Approved as proposed

7. **Ophthalmic Mast Cell Stabilizers**  
a. No change to the current classification of drug products – Approved as proposed

8. **Ophthalmic NSAIDs**  
a. No change to the current classification of drug products – Approved as proposed

**B. Cardiac:**

1. **ACE Inhibitors**  
a. No change to the current classification of drug products – Approved as proposed

2. **Alpha Adrenergic Agents**  
a. No change to the current classification of drug products – Approved as proposed  
b. **Remove reserpine from the PDL** – Approved as proposed

3. **Antihypertensive Combinations: ACEI-CCB**  
a. No change to the current classification of drug products – Approved as proposed

4. **Antihypertensive Combinations: ARB-CCB**  
a. No change to the current classification of drug products – Approved as proposed

5. **Angiotensin Receptor Antagonists (ARBs)**  
a. Move Benicar (olmesartan) and Benicar HCT (olmesartan/HCTZ) to non-preferred – Approved as proposed  
b. **Remove Entresto from the ARB subclass and create new cardiovascular subclass for Entresto - Angiotensin II-Receptor Neprilysin Inhibitors (ARNIs)** – Approved as proposed

6. **Direct Renin Inhibitors**  
a. No change to the current classification of drug products – Approved as proposed

7. **Beta Blockers**  
a. Move nadolol/bendromethazide (generic for Corzide) to non-preferred – Approved as proposed  
b. Move propranolol/HCT (generic for Inderide) to non-preferred – Approved as proposed

8. **Calcium Channel Blockers-Dihydropyridine**
a. No change to the current classification of drug products – Approved as proposed

9. Calcium Channel Blockers - Non-Dihydropyridine
a. No change to the current classification of drug products – Approved as proposed

10. Lipotropics - Antihypertensive Combinations
a. No change to the current classification of drug products – Approved as proposed

11. Lipotropics - Non-Statins: Fibric Acid Derivatives
a. Move fenofibrate (generic for Lofibra) capsules only to non-preferred – Approved as proposed

12. Lipotropics - Non-Statins: Bile Acid Sequestrants
a. Move colestipol (generic for Colestid) granules only to non-preferred – Approved as proposed

13. Lipotropics: Statins
a. Move Crestor to non-preferred – Approved as proposed
b. Move rosvastatin to preferred – Approved as proposed
c. Move pravastatin to preferred – Approved as proposed

14. Lipotropics: Niacin Derivatives
a. No change to the current classification of drug products

15. Lipotropics: Other
a. No change to the current classification of drug products – Approved as proposed

16. Lipotropics: PCSK9 Inhibitors
a. No change to the current classification of drug products – Approved as proposed

17. Anticoagulants
a. Move Eliquis (apixaban) to preferred – Approved as proposed
b. Move Arixtra (fondaparinux) to non-preferred – Approved as proposed
c. Move Fragmin (dalteparin) vials only to non-preferred – Approved as proposed

18. Antiplatelets
a. Move Brilinta (ticagrelor) to preferred – Approved as proposed

19. Pulmonary Arterial Hypertension (PAH) Agents
a. No change to the current classification of drug
b. Switch Opsumit to preferred without restriction
b. Table action on Uptravi pending further evaluation
Public Comments:

1. Rick Dettloff, PharmD, Pfizer, Inc., re. Eucrisa
2. Shefali Mihelich, Boehringer Ingelheim Pharmaceuticals, Inc., re. Stiolo Respimat and GOLD guidelines update
3. Ndidi Yaucher, PharmD, Novartis Pharmaceutical Corps., re. Tobi Podhaler
4. Zev Winicur, PhD, United Therapeutics, re. Orenitram ER Tablets

The meeting was adjourned at 8:22 PM

Next Meeting: Tuesday, June 13, 2017 Location: Kellogg Center